Equities research analysts expect that VBI Vaccines Inc (NASDAQ:VBIV) will post sales of $860,000.00 for the current quarter, according to Zacks. Two analysts have provided estimates for VBI Vaccines’ earnings. The highest sales estimate is $1.21 million and the lowest is $500,000.00. VBI Vaccines posted sales of $640,000.00 during the same quarter last year, which suggests a positive year over year growth rate of 34.4%. The company is scheduled to report its next quarterly earnings results on Friday, August 14th.
According to Zacks, analysts expect that VBI Vaccines will report full-year sales of $3.31 million for the current year, with estimates ranging from $2.00 million to $4.62 million. For the next year, analysts anticipate that the firm will report sales of $6.18 million, with estimates ranging from $4.10 million to $8.25 million. Zacks’ sales calculations are a mean average based on a survey of analysts that cover VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Wednesday, May 6th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.06) by $0.01. VBI Vaccines had a negative net margin of 2,133.79% and a negative return on equity of 57.79%. The firm had revenue of $0.42 million during the quarter, compared to the consensus estimate of $0.83 million.
Several equities analysts have weighed in on VBIV shares. Zacks Investment Research downgraded shares of VBI Vaccines from a “strong-buy” rating to a “hold” rating in a report on Thursday. BMO Capital Markets reaffirmed a “buy” rating and set a $4.00 price target on shares of VBI Vaccines in a research note on Monday. BidaskClub raised shares of VBI Vaccines from a “buy” rating to a “strong-buy” rating in a research note on Thursday, June 18th. Oppenheimer raised their price target on shares of VBI Vaccines from $5.00 to $8.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 23rd. Finally, Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price target on shares of VBI Vaccines in a research note on Friday, March 6th. Two investment analysts have rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. VBI Vaccines presently has an average rating of “Buy” and an average price target of $4.10.
NASDAQ:VBIV traded up $0.14 during mid-day trading on Monday, hitting $3.13. 11,861,720 shares of the company’s stock traded hands, compared to its average volume of 8,141,211. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.28 and a current ratio of 1.30. The firm’s 50 day simple moving average is $2.20 and its 200 day simple moving average is $1.47. VBI Vaccines has a 1 year low of $0.47 and a 1 year high of $3.50. The company has a market cap of $689.64 million, a PE ratio of -8.94 and a beta of 1.69.
In related news, major shareholder Life Sciences Maste Perceptive bought 9,090,909 shares of the firm’s stock in a transaction that occurred on Friday, April 24th. The shares were acquired at an average cost of $1.21 per share, with a total value of $10,999,999.89. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.00% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in VBI Vaccines by 13.0% during the first quarter. BlackRock Inc. now owns 11,678,848 shares of the biopharmaceutical company’s stock valued at $11,095,000 after buying an additional 1,341,519 shares in the last quarter. Geode Capital Management LLC lifted its position in VBI Vaccines by 67.6% during the fourth quarter. Geode Capital Management LLC now owns 2,447,848 shares of the biopharmaceutical company’s stock valued at $3,378,000 after buying an additional 987,072 shares in the last quarter. State Street Corp lifted its position in VBI Vaccines by 15.1% during the first quarter. State Street Corp now owns 2,362,367 shares of the biopharmaceutical company’s stock valued at $2,244,000 after buying an additional 310,001 shares in the last quarter. First Midwest Bank Trust Division lifted its position in VBI Vaccines by 42.3% during the first quarter. First Midwest Bank Trust Division now owns 2,032,457 shares of the biopharmaceutical company’s stock valued at $1,931,000 after buying an additional 604,051 shares in the last quarter. Finally, Nuveen Asset Management LLC lifted its position in VBI Vaccines by 53.6% during the first quarter. Nuveen Asset Management LLC now owns 639,155 shares of the biopharmaceutical company’s stock valued at $607,000 after buying an additional 223,118 shares in the last quarter. 33.88% of the stock is currently owned by institutional investors and hedge funds.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Recommended Story: Cash Asset Ratio
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.